Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02454699 · ClinicalTrials.gov registry record · Phase 1
Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers
A Phase 1 study of Cytomegalovirus Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02454699 is a Phase 1 study of Cytomegalovirus Infection that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 24 participants, below the 239-participant average among 5 other Cytomegalovirus Infection trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02454699, a Phase 1 study of Cytomegalovirus Infection, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase I safety, PK and food effect study of the CMV drug. In part 1 of the study, subjects will receive one of four dosage strengths of MBX-400 (100 mg once daily, 350 mg once daily; 750 mg once daily; and 1000 once daily) for 7 days and safety and PK will be assessed. Subjects must be 18 to 65 years of age, male or female; if female, be surgically-sterilized or post-menopausal; if male, have undergone vasectomy; have a body mass index (BMI) of 18 to 32 kg/m\^2; not be a user of nicotine-containing products; be willing to abstain from nicotine-containing products, alcohol and illicit drugs during the study. Subjects will be followed for 28 days post dosing.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG MBX400
Study Locations (1)
Georgia
- Emory Vaccine Center - The Hope Clinic - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-11-10 |
| Est. Completion | 2017-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02454699
The ClinicalTrials.gov registry entry for NCT02454699 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 5 other Cytomegalovirus Infection trials with a reported enrollment target (90% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cytomegalovirus Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02454699 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT02454699 about?
NCT02454699 is a clinical study titled "Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers". This is a phase I safety, PK and food effect study of the CMV drug. In part 1 of the study, subjects will receive one of four dosage strengths of MBX-400 (100 mg once daily, 350 mg once daily; 750 mg once daily; and 1000 once daily) for 7 days and safety and PK will be assessed. Subjects must be 18 ...
What is the current status of trial NCT02454699?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2015-11-10. Estimated completion is 2017-12-01.
What conditions does trial NCT02454699 study?
This clinical trial studies the following conditions: Cytomegalovirus Infection.
What interventions are being tested in trial NCT02454699?
The interventions under investigation include: Placebo (OTHER), MBX400 (DRUG).
Who is sponsoring clinical trial NCT02454699?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02454699 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytomegalovirus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge
COMPLETED · Phase 1
-
A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.
RECRUITING · Phase 2
-
Dried Blood Spot Testing of CMV Detection in HCT Recipients
COMPLETED · NA
-
Cytomegalovirus (CMV) Infection in Pregnancy
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.